We draw on our diverse experience and global relationships
Chief Executive OfficerRead Bio
Khoo Shih has been integral to establishing ClavystBio. As Managing Director of Life Sciences Investments at Temasek, she was part of the founding team that conceived and formed ClavystBio.
Khoo Shih is passionate about accelerating innovations and transforming human health. She has over 20 years of experience investing in private and public life sciences and healthcare companies globally. During her career at Temasek, she successfully grew the life sciences portfolio and led biopharma and early stage innovation investments and strategies.
Prior to joining Temasek, Khoo Shih was with UOB Venture Management and was responsible for investing in life sciences venture and growth companies in China and USA. She started her business career in the Biomedical Sciences cluster at the Singapore Economic Development Board and was part of the team that spearheaded the growth of the biomedical industry in Singapore.
Khoo Shih attained her PhD in Genetics and Development from the University of Texas Southwestern Medical Center, USA and BSc in Microbiology from National University of Singapore.
Chief Operating OfficerRead Bio
Michelle has been instrumental in forming ClavystBio and shaping the company’s strategy. She brings over 17 years of experience in finance and operations.
Michelle is currently seconded from Temasek International where she was most recently Director (Enterprise Development Group). She has been with Temasek since 2010 and has had past roles in Investments (Financial Services) and the Investment Group Office. Prior to Temasek, Michelle was an investment banker at Credit Suisse Singapore and Credit Suisse New York.
Michelle holds a BSc in Management Engineering (Honorable Mention) from the Ateneo de Manila University, Philippines, and an MBA (with Distinction) from Johnson Graduate School of Management, Cornell University, USA. She is also an alumna of London Business School, UK (exchange programme).
Venture Building & Investing
Wen Qi HO
Therapeutics LeadRead Bio
Wen Qi focuses on investing in and building global healthcare companies from Singapore. Prior to joining ClavystBio, she headed up the Singapore investments and operations for Lightstone Ventures, where she played a major role in establishing the firm’s presence in Singapore. Wen Qi evaluated new investment opportunities in the biopharmaceutical and medical device sectors, and was actively involved in venture-building portfolio companies in Singapore such as Medisix Therapeutics, Allay Therapeutics and Ligature Therapeutics.
Wen Qi is an advocate for early career researcher participation in biotech entrepreneurship, and serves on advisory and grant review panels with leading institutions in Singapore. She also serves on boards of ClavystBio’s portfolio companies.
Wen Qi attained her PhD in Immunology at Stanford University, and BSc in Molecular and Cellular Biology at Johns Hopkins University.
Vice President, TherapeuticsRead Bio
Yvonne brings a unique blend of commercial and public sector experience to investing and venture building at ClavystBio. Her multi-faceted career includes roles in venture capital investing, business strategy, product development, technology commercialization, and innovation policy across the biotech and medtech sectors.
Yvonne was previously at Lightstone Ventures (LSV) and was involved in due diligence and program management for the firm’s early-stage ventures globally and in Singapore. Prior to that, Yvonne was Deputy Director at the National Research Foundation where she led the development and implementation of Singapore’s innovation strategy. She has also held operational roles at a Singapore-based medical diagnostics start-up.
Yvonne attained her PhD in Biochemistry from the University of Wisconsin Madison, USA, and a BSc in Molecular Biology from the University of Illinois Urbana-Champaign, USA.
Director, Digital HealthRead Bio
Yingmin brings the rigour of a scientist to business strategy. She has led business development, partnerships and R&D in hi-tech sectors such as life sciences, agrifood and semiconductors. Her passion for accelerating technology translation into healthcare solutions brought her to ClavystBio.
Yingmin’s experience spans both the private and public sector. She has held positions at Applied Materials South East Asia, the Singapore Economic Development Board and A*Star.
Yingmin attained her PhD in Bioengineering from the California Institute of Technology (Caltech), USA, and BSc in Biomedical Engineering from Duke University, USA.
Assistant Vice President,
Nigel focuses on growing ClavystBio’s business and investment platforms. He is a believer in biology as technology for human wellness, and excited about building the next generation of life sciences innovations through Singapore.
Nigel previously ran venture building and investment platforms for large multinationals and private family offices. Prior to that, he worked at the Singapore Economic Development Board managing the Republic’s inbound investments in the chemicals, synthetic biology and food industries. He played a key role in originating investments, as well as developing national infrastructure to ensure the long term success of these industries.
Nigel holds a BA in Management (Magna Cum Laude) from Singapore Management University. Alongside his work in ClavystBio, Nigel is also the founder of Next Billion Burgers, a global movement to create an open source community in the plant-based food industry, with a goal of enabling plant-based foods that are affordable, nutritious and sustainable.
Advisor, Digital HealthRead Bio
Sang has spent his career disrupting, developing and rethinking systems. At ClavystBio, his focus is to build a digital health innovation engine that will help catalyse collaboration between ecosystem constituents.
Sang was previously Director (Enterprise Development Group) at Temasek International. He introduced and fostered tech innovations at Temasek and its portfolio companies through accelerators, labs, and global startup ecosystem partnerships. Before joining Temasek, Sang held positions at GIC, Bridgewater Associates, and McKinsey & Company.
Prior to moving to Singapore, Sang was based in Silicon Valley where he co-founded Been, Inc and developed the world’s only mobile app that enabled users to monetise and control their personal data and privacy.
Sang holds a BA in Economics, and BSc in Environmental Science from Tufts University, USA.
Charles Yiliu ZHANG
Senior AssociateRead Bio
Charles is energized by the accelerating pace of innovation in biomedical research, and the potential of fledgling startups to create life changing medicines and devices. At ClavystBio, he draws upon his diverse background in science, intellectual property (IP), and venture investment to help scientists and start-ups create lasting impact for patients across the world.
Charles started his career as a post-doctoral research scientist at the Institute of Cell & Molecular Biology (IMCB), A*STAR and later worked as a trainee patent attorney at an international firm. Before joining ClavystBio, Charles was in a Singapore based biotech VC focusing on venture creation and investment.
Charles attained his PhD in Cell and Molecular Biology from the National University of Singapore (NUS), and BSc in Life Science from Sun Yat-sen University, China. He also holds a Graduate Certificate in IP from the Faculty of Law, NUS and IP Academy Singapore.
Senior AssociateRead Bio
Ning is passionate about the business of science, and in particular the process of translating scientific research into exciting companies. She channels this passion into investment and venture creation work at ClavystBio to help realize the commercial value and medical benefits of life sciences innovations in Singapore.
Before joining ClavystBio, Ning worked at a venture firm focusing on early-stage biotech investments. She worked closely with portfolio companies and gained biotech operations and business development experience. Prior to that, she was a consultant advising clients in the life sciences industry on commercial strategy.
Ning holds a PhD in Biomedical Engineering from Boston University, USA, and BSc in Bioengineering from Nanyang Technological University, Singapore.
Legal LeadRead Bio
Jason oversees the legal facets of venture building at ClavystBio, bringing his legal expertise and entrepreneurial experience to guide business strategy, venture capital financing and public private partnerships. Having been with multiple start-ups, Jason has a deep understanding of the needs of founders and early-stage companies, and is sensitive in navigating board and shareholder dynamics.
Previously General Counsel at a leading biotech start-up in the cell and gene space, Jason was instrumental in orchestrating its largest fundraise of US$100+M and executed a carve-out of its manufacturing operations. While General Counsel at V-Key, a cybersecurity and fintech start-up, he implemented a channel partner strategy resulting in hyper-growth across 3 regions.
Jason holds a BA in Jurisprudence from Oxford University, UK, and an MBA from INSEAD, France. He is also a Kellogg School of Management alumnus (USA exchange program).
Nge Hwee NG
Operations LeadRead Bio
Nge Hwee drives operations at ClavystBio, and looks at improving connectivity and collaboration among players within the life sciences ecosystem. A founding member of the team, she is energised by the zero-to-one environment of setting up a new platform, and the potential impact of ClavystBio’s work.
Nge Hwee is currently seconded from Temasek International where she was most recently Vice President (Enterprise Development Group). She has been with Temasek since 2014. Prior to Temasek, Nge Hwee was with the Corporate Finance and Valuations teams at PricewaterhouseCoopers.
Nge Hwee holds a double degree in Business and Accountancy (First Class Honours) from Nanyang Technological University, Singapore.
Communications LeadRead Bio
Patricia believes in broadening people’s perspectives and bridging differences through stories. She is excited about ClavystBio’s mission to drive health impact, and inspiring ever-expanding networks and communities with new ideas and knowledge.
Patricia began her career as a journalist, working for the Daily Telegraph magazine, Financial Times How to Spend It, and SPH magazines. Prior to joining ClavystBio, she oversaw content development at National Gallery Singapore, and taught journalism at LASALLE College of the Arts and Singapore Polytechnic. She has contributed to titles including T: The New York Times Style Magazine, Monocle, and The Straits Times.
Patricia holds an LLB (Hons) from the London School of Economics and Political Science, UK
Manager, Lab Safety & FacilitiesRead Bio
Regis is overseeing the development of ClavystBio’s lab facility and infrastructure at Science Park. A champion for co-working labs, he sees them as the solution to the huge gap between spin-offs and manufacturing that many scientists fail to overcome. “They solve the primary problem of the sheer expense of building a lab, and allow scientists to do what they do best – bump heads and collaborate to generate new ideas.”
Prior to joining ClavystBio, Regis was Technical Head for Fuchs Singapore and a founding team member of Life Science Incubator. He also has extensive experience managing quality control for leading pharma MNCs.
Regis holds a Bsc in Biomedical Sciences from the University of Bradford, UK.
Manager, Finance & ComplianceRead Bio
Samantha supports ClavystBio on finance and compliance matters. She believes that finance is a powerful tool in ensuring company growth and ongoing success.
Samantha started her career in the Governance, Risk and Advisory team at KPMG, gaining experience in enterprise risk management, compliance review and internal audit reviews in Singapore and overseas. She then joined Lightstone Ventures, where she focused on setting up and supporting the smooth running of finance functions and operations in early-stage life science ventures.
Samantha holds a BAcc with a second major in Finance from Singapore Management University.
Executive AssistantRead Bio
Rachel has been supporting executive teams and finessing the details of jam-packed schedules for over 15 years. She brings an admirable calm, coupled with attention to detail, to the administrative operations at ClavystBio.
Rachel was previously a Talent Administrator & Coordinator at executive search firm Profile, and prior to that worked at Michael Page and Keppel Land.
Executive AssistantRead Bio
Sophia makes the trains run on time at ClavystBio. She specialises in administrative technology, and manages schedules and provides administrative support to the CEO and team.
Sophia has over 10 years of experience working alongside senior management in financial institutions and MNCs including Temasek International, NETS and EY.
Independent DirectorRead Bio
Amy Schulman is a Managing Partner in Polaris Partners’ New York office and focuses on investments in healthcare companies. She also manages the Polaris Innovation Fund.
Prior to Polaris, Amy held various roles at Pfizer including President of Pfizer Consumer Healthcare, President of Pfizer Nutrition where she was instrumental in its sale to Nestle in 2012, and General Counsel of Pfizer.
Amy currently serves as Executive Chair of SQZ Biotech, and as a director of Alnylam Pharmaceuticals and Mount Sinai Hospital in New York City.
Dr Fidah Alsagoff is Joint Head of the Enterprise Development Group (Singapore) and Head of Life Sciences at Temasek International.
He was previously a Partner at Innosight Ventures Pte Ltd and prior to that, was Chief Executive Officer of Ministry of Health Holdings. Fidah’s career also includes nearly a decade in social entrepreneurship where he established several programmes and enterprises catering to unmet healthcare needs of patients. The latest among these was the Singapore Cord Blood Bank.
Fidah graduated from the National University of Singapore with a Bachelors of Medicine and Surgery, and later with a Masters of Medicine in Public Health. He attended INSEAD on a Lee Kuan Yew Scholarship for post-graduate studies, and subsequently graduated with an Executive MBA (with distinction). As valedictorian of his EMBA class, he was awarded the Claude Janssen Prize.
Fidah currently serves on the Board of Trustees of the Singapore University of Technology and Design, and on the Governing Board of the Duke-NUS Medical School.
Independent DirectorRead Bio
Ken spent the early years of his career working across the industries of agriculture, finance, and retail, before finding a home in healthcare. Since then, he has focused on using data, analytics, and a longitudinal understanding of disease to build products and businesses that improve the healthcare system. His career spans three decades and consists of numerous leadership positions and entrepreneurial endeavors, including serving as UnitedHealth Group’s Chief Scientific Officer.
Ken has founded and successfully exited several companies, including All Savers—a novel insurance product for small businesses that brings the advantages of large groups, Motion—the first payfor-healthy-behaviors insurance program that used biosensors, Level2—the first insurance plan that combines disease-specific interventions with benefit design, and Savvysherpa—a healthcare R&D firm focused at the intersection of math, clinical science, and human connection.
Today, Ken is most passionate about the linkage between cognition, behavior, biology, and chronic diseases. His efforts are aimed at exploring this linkage and harnessing it to improve health and access to healthcare, especially for those who are socio-economically challenged.
Independent DirectorRead Bio
Dr Ranga Krishnan is Senior Advisor to the Rush University System for Health in Chicago, and Chairman of the National Medical Research Council (NMRC) in Singapore.
He was previously Dean of Rush Medical College, and Chief Executive Officer of the Rush University System for Health. Ranga advanced the innovation of care delivery by organising providers around patients, diseases and conditions rather than by department or division to enable greater multidisciplinary collaboration. He also remodelled Rush’s innovation and technology strategy, including the Innovation and Technology Transfer Office which manages Rush’s intellectual properties.
Prior to Rush, Ranga was Dean of Duke-NUS Graduate Medical School Singapore, where he developed a teaching method called Team LEAD (Learn, Engage, Apply, Develop) which has since been adopted by other universities and high schools.
Independent DirectorRead Bio
Steve Krognes is a professional board member in the biotech and life science sector. He currently serves as a Director at Denali Therapeutics, Guardant Health, Gritstone bio and argenx, all publicly listed companies, and previously served on the boards of Corvus Pharmaceuticals, RLS Global AB and Tessa Therapeutics.
Previously, Steve worked 7 years as CFO of Denali Therapeutics, 6 years as CFO of Genentech and 6 years as global head of M&A at Roche. At Denali, Steve built the finance, IT and site organizations, and led the company’s IPO and capital raising efforts. At Genentech, Steve led the integration of InterMune as well as the integration of Roche and Genentech, chaired the Genentech Access to Care Foundation and represented Genentech on the Board and Executive Committee of the California Life Science Association. At Roche, under Steve’s leadership, the M&A team executed more than 30 transactions worldwide, and he personally led the acquisition of and subsequent integration of Genentech.
Prior to that, Steve worked as an investment banker at Goldman Sachs, a management consultant at McKinsey, and as a venture capitalist in Scandinavia. Steve holds an M.B.A. from Harvard Business School, a B.S. in Economics from the Wharton School of the University of Pennsylvania. Steve grew up in Norway and is a second lieutenant in the Royal Norwegian Air Force, and speaks Norwegian, French, and conversational German. Steve lives in Cannes (France) and San Francisco (USA) with his family.
Independent DirectorRead Bio
Dr Vicki Sato is a Venture Partner at ARCH Venture Partners, Chairman of Vir Biotechnology and Denali Therapeutics, and a business advisor to several enterprises in the biotechnology and pharmaceutical industries.
Vicki was previously a Professor of Management Practice at Harvard Business School and a Professor of the Practice, Molecular and Cell Biology, for Harvard’s Faculty of Arts and Sciences. Prior to that, Vicki spent many years in the industry, including most recently as President of Vertex Pharmaceuticals.
Vicki is a member of the President’s Council of Advisors on Science and Technology (PCAST) in the United States, and was the inaugural Co-Chair of the Advisory Council for the NYC LifeScience Initiative to establish New York City as a global leader in life sciences.
Dr. Amy Abernethy is the President of Product Development and Chief Medical Officer at Verily, where she leads teams in the development and delivery of products that bridge the gap between clinical research and care.
Dr. Abernethy was most recently Principal Deputy Commissioner of Food and Drugs of the US Food and Drug Administration (FDA) and the agency's acting Chief Information Officer. Prior to her role at the FDA, Dr. Abernethy was Chief Medical Officer, Chief Scientific Officer and Senior Vice President of Oncology of Flatiron Health. Before joining Flatiron, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine and directed the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute.
Dr. Abernethy is a hematologist/oncologist and palliative medicine physician who has authored more than 500 publications. She holds a BA in Biochemistry from the University of Pennsylvania, an MD from Duke University School of Medicine, and a PhD in Evidence Based Medicine and Informatics from Flinders University in Australia.
Dr. Robert Langer is one of 9 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member. He has written over 1,500 articles, which have been cited over 401,000 times. His h-index of 315 is the highest of any engineer in history and the 2nd highest of any individual in any field. His patents have licensed or sublicensed to over 400 companies, and he is a cofounder of a number of companies including Moderna.
Dr. Langer served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of 3 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, Hoover Medal, Dreyfus Prize in Chemical Sciences, BBVA Frontiers of Knowledge Award in Biomedicine, and the Balzan Prize.
He holds 41 honorary doctorates, including Harvard, Yale, Columbia, and Northwestern, and has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.